Genetic evidence for the bidirectional modulation of synaptic plasticity in the prefrontal cortex by D1 receptors

  1. Yan-You Huang*,
  2. Eleanor Simpson*,,
  3. Christoph Kellendonk*, and
  4. Eric R. Kandel*,,
  1. *Center for Neurobiology and Behavior and Howard Hughes Medical Institute, College of Physicians and Surgeons, Columbia University, New York, NY 10032
  1. Contributed by Eric R. Kandel, January 19, 2004

Abstract

To address the role of D1 receptors in the medial prefrontal cortex, we combined pharmacological and genetic manipulations to examine long-term synaptic potentiation (LTP)/long-term synaptic depression (LTD) in brain slices of rats and mice. We found that the D1 antagonist SCH23390 selectively blocked the maintenance but not the induction of LTP in the prefrontal cortex. Conversely, activation of D1 receptors facilitated the maintenance of LTP, and this effect is impaired in heterozygous D1 receptor knockout mice. Low-frequency stimulation induced a transient depression in the medial prefrontal cortex. This depression could be transformed into LTD by coapplication of dopamine. Coapplication of dopamine, however, shows no facilitating effect on LTD in heterozygous D1 receptor knockout mice. These results provide pharmacological and genetic evidence for a role of D1 receptors in the bidirectional modulation of synaptic plasticity in the medial prefrontal cortex. The absence of this modulation in heterozygous knockout mice shows that a dysregulation of dopamine receptor expression levels can have dramatic effects on synaptic plasticity in the prefrontal cortex.

Footnotes

  • To whom correspondence should be addressed at: Columbia University, 1051 Riverside Drive, New York, NY 10032. E-mail: erk5{at}columbia.edu.

  • Abbreviations: LTP, long-term synaptic potentiation; LTD, long-term synaptic depression; NMDA, N-methyl-D-aspartate; mPFC, medial prefrontal cortex; fEPSP, field excitatory postsynaptic potential; D-APV, D-2-amino-5-phosphonovaleric acid; 6-APB, 6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide; PKA, protein kinase A.

« Previous | Next Article »Table of Contents